Disease · HP_0002121
Generalized non-motor (absence) seizure
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Generalized non-motor (absence) seizure. Diseases, record HP_0002121. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002121
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Generalized non-motor (absence) seizure
- Open Targets ID
- HP_0002121
- Other names
- Absence seizure, Absence seizures, Brief seizures with staring spells, Generalised non-motor (absence) seizure, Generalised non-motor seizure, Petit mal, Petit mal seizure, Petit mal seizures
- Highest stage of its drugs
- Approval, for 2 of its 6 drugs, from DailyMed
Source Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DIVALPROEX SODIUM | CHEMBL2105613 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| VALPROIC ACID | CHEMBL109 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| FENFLURAMINE HYDROCHLORIDE | CHEMBL2106217 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEVETIRACETAM | CHEMBL1286 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CANNABIDIOL | CHEMBL190461 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LAMOTRIGINE | CHEMBL741 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets17
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ALDH5A1 | Succinate-semialdehyde dehydrogenase, mitochondrial | 2 | Succinate semialdehyde dehydrogenase inhibitor | Approval | https://conductscience.org/library/genes/7915 | Drugs and targets |
| CACNA1B | Voltage-dependent N-type calcium channel subunit alpha-1B | 1 | Voltage-gated N-type calcium channel alpha-1B subunit blocker | Phase 3 | https://conductscience.org/library/genes/774 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 1 | Cannabinoid CB1 receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| HTR1D | 5-hydroxytryptamine receptor 1D | 1 | Serotonin 1d (5-HT1d) receptor agonist | Phase 3 | https://conductscience.org/library/genes/3352 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 1 | Serotonin 2c (5-HT2c) receptor agonist | Phase 3 | https://conductscience.org/library/genes/3358 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 1 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 1 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 1 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 1 | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 1 | https://conductscience.org/library/genes/6328 | Drugs and targets |
1 to 10 of 17
See all 17 targetsTrials4
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03790137 | Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25). | Phase 3 | 20 | 2023-02-08 | Photosensitive Epilepsy | FENFLURAMINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03355300 | Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures | Phase 2 | 11 | 2023-06-18 | Childhood Absence Epilepsy | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov |
| NCT00150748 | Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy | Phase 3 | 217 | Generalized Epilepsy | LEVETIRACETAM | Its record names the disease | ClinicalTrials.gov | |
| NCT00144872 | LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures | Phase 1 | 54 | Seizure, Absence | LAMOTRIGINE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Canabidiol Oral Solution 20 to <30 mg/kg/Day vs Canabidiol Oral Solution 30 to <40 mg/kg/Day: deaths from any cause | 0 of 5 | 0 of 6 | 11 | NCT03355300 | Trial comparisons |
| Canabidiol Oral Solution 20 to <30 mg/kg/Day vs Canabidiol Oral Solution 30 to <40 mg/kg/Day: serious adverse events | 0 of 5 | 0 of 6 | 11 | NCT03355300 | Trial comparisons |
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002121
GET https://conductscience.org/api/diseases/v1/HP_0002121/drugs